Medicines Press Releases

03.08.2018

Pfizer Announces Favorable Outcome of FDA Advisory Committee Meeting on XELJANZ® (tofacitinib) for Moderately to Severely Active Ulcerative Colitis

02.23.2018

Pfizer Receives Positive CHMP Opinion for Two Hematology Medicines, MYLOTARG™ and BOSULIF®

02.23.2018

Pfizer Announces Update on European Marketing Authorization Application for SUTENT® (sunitinib) in Adult Patients at High Risk of Recurrent Renal Cell Carcinoma

02.14.2018

Pfizer Receives Breakthrough Therapy Designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis

01.24.2018

Pfizer Announces Positive Top-Line Results For Potential Biosimilar To Rituxan®/MabThera®

12.12.2017

U.S. Food And Drug Administration Extends Action Date For XELJANZ® (Tofacitinib) Supplemental New Drug Application In Ulcerative Colitis By Three Months

09.21.2017

New Global Report Finds Majority of People at High Risk of Stroke Not Being Screened for Common Risk Factors

05.17.2017

Pfizer Oncology to Present Data Across 13 Different Types of Cancer at ASCO 2017 Annual Meeting